Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer Authors M. Di Maio Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy. G. Daniele Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy. M.C. Piccirillo Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy. Abstract No abstract available